
Sign up to save your podcasts
Or


In this randomized trial, momelotinib was non-inferior to ruxolitinib for spleen response but was less effective in controlling symptoms.
Related Article: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
In this randomized trial, momelotinib was non-inferior to ruxolitinib for spleen response but was less effective in controlling symptoms.
Related Article: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

14,359 Listeners

139 Listeners

319 Listeners

498 Listeners

58 Listeners

112,751 Listeners

44 Listeners

32 Listeners

195 Listeners

91 Listeners

363 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners